Introduction
The journey of “ketamine” dates back to the 1950s when scientists at Park Davis Laboratories,
Detroit, Michigan, formulated phencyclidine (PCP), trials of which were conducted
on humans in 1958 under the name of Sernyl. With growing clinical evidence, it became
clear that PCP was not suitable for human anesthesia. One of its derivatives, synthesized
in 1962 by Calvin Stevens, led to excellent short-acting anesthesia. It was selected
for clinical trials in humans as CI-581 [2- (O-chloro-phenyl)-2-methylamino cyclohexanone].[1] As it was a ketone together with an amine, it was named “ketamine.” The commercially
available ketamine is a racemic mixture of two enantiomers R (−) ketamine and S (+)
ketamine. S (+) isomer has four times greater affinity for the NMDA receptors than
R (−) isomer, and thus it has a greater anesthetic and analgesic potency.
The burden of ischemic injury to the brain, for example, in cerebrovascular accident
(CVA), traumatic brain injury (TBI), tumors, hemorrhage, etc. is ever increasing,
many of which requiring a neurosurgery. Continued advancements in anesthetic treatments
during the perioperative period may be one of the significant ways to improve the
overall patient outcomes. An ideal neuroanesthetic agent should possess neuroprotective
properties such as reducing cerebral metabolic rate (CMRO2) and cerebral blood volume (CBV), preventing increase in intracranial pressure (ICP),
maintaining cerebral autoregulation and CO2 reactivity, preventing seizure activity. Also, it should neither be a vasodilator
or a myocardial depressant nor an adrenal suppressant. However, till date, an ideal
neuroanesthetic agent is yet to be available in clinical practice.
Mechanism of Action: Neuropharmacology
Ketamine is an intravenously administered general anesthetic agent that primarily
acts through noncompetitive binding to the N-methyl-D-aspartate (NMDA) receptor.[2] The secondary mechanisms of action include those at the µ opioid, muscarinic and
monoaminergic receptors, voltage-gated sodium, and the L-type calcium channels.[3]
[4]
[5]
[6] It is also known to inhibit interleukin-6 (IL-6) and catecholamine reuptake.[7] These mechanisms clinically lead to induction of a dissociative cataleptic state
and also provide analgesia, hypnosis, bronchodilation, and sympathetic stimulation.[8] This is clinically advantageous as administering ketamine with a γ-aminobutyric
acid (GABA) agonist reduces its sympathomimetic effect that results in a stable hemodynamic
state and reduces the patient's requirement for vasoactive medications.[9]
The traditional pharmacologic neuroprotection with neuroanesthetics is achieved by
increasing oxygen delivery and decreasing the pathologic mechanisms that result in
neuronal cell death.[10] Glutamate excitotoxicity is the principal mechanism of neuronal cell death, and
unlike other anesthetic agents, ketamine possesses a unique pharmacologic property
of antagonizing this excitotoxicity via NMDA receptor upregulation during cerebral
ischaemia.[11] However, ketamine has not been so widely used in neurosurgical anesthesia practice
due to the concerns of increasing CBV, which contributes to rise in ICP. Earlier studies
noted a rise in ICP with the use of ketamine for sedation in spontaneously breathing
patients that led to hypercarbia, and hence cerebral vasodilation.[12] Recent literature and reevaluation of this subject have paved the way of how this
drug should be looked at and made us rethink the paradigm, thus revisiting its role
in neuroanesthesia practice. It has now been clarified that using ketamine as an adjuvant
to other neuroanesthetic agents with maintenance of normocapnia through mechanical
ventilation does not lead to increase in ICP.[13]
[14]
[15]
[16]
Another beneficial effect of ketamine in neurosurgical patients is through occurrence
of both neuroprotective properties of physiological synaptic NMDA receptor activation
and neurodestruction caused by excitotoxic extrasynaptic NMDA receptor activation.
Under physiologic states, ketamine is known to oversuppress the physiologic NMDA receptor
activation preventing the neuroprotective cascade.[17] However, when administered during cerebral ischemia, it antagonizes the glutamate
activation of the extrasynaptic NMDA receptor activation, thus preventing the neurodestructive
cascade and reducing neuronal cell death.
Mechanism of Neuroprotection
There are different neuroprotective and neurodestructive pathways mediated through
synaptic and extrasynaptic NMDA receptor activation. Under physiologic conditions,
the beneficial effects are mediated through phosphoinositide-3-kinase (PI3K)-AKT pathway
that inhibits proapoptotic glycogen synthase kinase 3 β (GSK3β), forkhead box O (FOXO),
and p53 transcription factor genes.[18]
[19]
[20]
[21]
The synaptic stimulation of NMDA receptor also activates striatal-enriched tyrosine
phosphatase (STEP) degradation along with extracellular signal-regulated kinase ½
(ERK½) activation, leading to cell survival.[22] Also, the associated Ca2+ influx stimulates CREB (cyclic adenosine monophosphate [cAMP] response element-binding
protein) that increases tolerance of neurons to ischemic events, thus delaying apoptosis
and in turn also explaining neuronal ischemic preconditioning.[19]
[23] All these pathways are triggered by synaptic NMDA receptor activation, which may
be oversuppressed by ketamine leading to neurodestruction under physiologic conditions.
However, under ischemic conditions, use of ketamine is advantageous. Ischemia induces
excitotoxic process involving presynaptic release of large amounts of glutamate, which
stimulates extrasynaptic NMDA receptors.[23] These higher levels of glutamate then overactivate postsynaptic NMDA receptor protein
kinase C and tyrosine kinase signaling cascades.[24]
[25] They phosphorylate the NMDA receptors and upregulate the signaling currents, thus
amounting to increase in NMDA receptor activation. Whenever there is increase in excitotoxic
glutamate release, it is the extrasynaptic NMDA receptors that mediate neurodestruction
and override neuroprotective pathways.[23]
[25] Extrasynaptic NMDA receptor activation induces neuronal injury by causing excessive
influx of Ca2+, which, in turn, activates calpain, disabling the Na+/Ca2+ exchanger and decreases Ca2+ efflux, further augmenting apoptosis.[26] This Ca2+ also activates neuronal nitric oxide synthase leading to overproduction of nitric
oxide (NO) and damaging the mitochondria. In addition, calpain breaks down STEP, activates
p38, and promotes nuclear import of FOXO.[27] These pathways ultimately culminate in cell death by apoptosis or necrosis.
Review of Clinical Evidence
Ketamine has been under extensive clinical research since its introduction in the
1960s. Earlier it was discouraged in neurosurgical patients due to the concerns of
raised ICP. However, ample clinical evidence now supports its use even in patients
with neurosurgical pathologies as it does not have any deleterious cerebral hemodynamic
or neurologic consequences.
Traumatic Brain Injury
Bar-Joseph et al[13] studied neurologic effects of ketamine prospectively in intubated children with
raised ICP who were sedated with midazolam, 2 to 5 µg/kg/min, and morphine, 20 to
50 µg/kg/min. They were administered ketamine boluses (1–1.5 mg/kg) during episodes
of ICP elevation and before any sort of stimulating events. The authors observed that
ketamine decreased the ICP by an average of 30% (p < 0.001) and achieved modest increase in cerebral perfusion pressure (CPP) (p < 0.005). This study concluded that, for neurosurgical sedation, adjuvant administration
of ketamine with other anesthetic agents resulted in favorable cerebral hemodynamic
responses.
Bourgoin et al[14] conducted a randomized, double-blinded, trial comparing patients with TBI in the
intensive care unit (ICU) who received sedation with either ketamine/midazolam or
sufentanil/midazolam, and they observed no statistical difference in ICP between the
two groups (p = 0.28). Six months postinjury, the Glasgow outcome score (GOS) of each group was
measured to determine neurologic function of each patient, and no statistical difference
could be discerned (p = 0.99). Similarly, a retrospective study was conducted by Grathwohl et al[28] who compared the neurologic outcome of 252 patients with TBI receiving total intravenous
anesthesia (TIVA) with propofol and ketamine to TIVA without ketamine and to volatile
anesthesia without ketamine. They concluded that there was no statistically significant
difference in the number of patient deaths between the groups (p = 0.36) and no statistical difference in the GOS of each group (p = 0.47). Both these studies illustrated that as an adjuvant, ketamine did not worsen
patient outcomes and was statistically indifferent from the outcomes of patients who
received anesthesia with volatile anesthetics, propofol, opioid, or benzodiazepines.
Långsjö et al[12] studied that ketamine led to an increase in regional cerebral blood flow in the
anterior cingulate and frontal cortices and observed that CMRO2 did not directly correlate with cerebral blood flow changes. It did not increase
after ketamine was administered. However, this study was performed in spontaneously
breathing individuals, and the results cannot be extrapolated to neurosurgical patients
who usually are under controlled mechanical ventilation with maintenance of normocarbia.
In a meta-analysis published by Cohen et al[29] regarding the effects of ketamine on intracranial and cerebral perfusion pressure
and health outcomes that included 10 studies and 953 critically ill patients. Two
studies reported a slight decrease in ICP within 10 minutes of ketamine administration,
and two studies reported an increase. However, none of the studies reported significant
differences in CPP, neurologic outcomes, ICU length of stay, and mortality. Another
recent meta-analysis published by Zeiler et al[30] included studies of 101 adult and 55 pediatric patients and stated that ICP did
not increase in any of these studies during ketamine administration. Rather, three
studies reported a significant decrease in ICP with ketamine bolus. There currently
exists Oxford level 2b, grade C evidence to support that ketamine does not increase
ICP in severe TBI patients who are sedated and ventilated, and in fact, may lower
it in selected cases.
In TBI, the contused segment of the brain forms the core and is usually surrounded
by a penumbra of “at risk” tissue that may suffer secondary brain injury. Use of ketamine
that causes an increase in mean arterial pressure and possibly an increase in CPP
may lead to increased cerebral blood flow to these “at risk” and vulnerable areas,
thereby preventing secondary ischemic injury.
Ketamine, when used as an induction agent for rapid sequence intubation in undifferentiated
critically ill patients or patients with major trauma where neurologic injury has
not been ruled out, still remains an inconclusive debate for emergency physicians.
A very essential role of the emergency care provider managing such a patient is to
ensure minimal secondary insults to the brain during the resuscitation phases of the
patient's care. These patients might be irritable, in pain, and combative, and hence
prone to a high systemic sympathetic response, and thus already raised ICP. Thiopentone,
propofol, or fentanyl might lead to significant hypotension during induction, particularly
in hypovolemic patients, which might worsen outcome of such patients.
Various studies have established a strong association between the degree and duration
of hypotension (a systolic blood pressure of < 90 mm Hg in adults) and worse neurologic
outcomes in patients with TBI. Hence, it is imperative to avoid using induction agents
such as barbiturates, opioids, and benzodiazepines that cause or may exacerbate any
preexisting hemodynamic instability and may worsen the hypotension and cause further
cerebral ischemia. Ketamine, having the advantage of maintaining a neutral hemodynamic
profile, may be safely used.[31] Etomidate may have an edge over other induction agents in this regard. However,
in light of the uncertainty over the clinical significance of the adrenal suppression
associated with it and the frequent occurrence of sepsis in patients with major trauma,
the available evidence suggests that ketamine should be considered as an alternative
induction agent or as an adjunct to other intravenous (IV) agents.[32] The current practice of avoiding ketamine in rapid sequence induction and intubation
of head-injured patients, for the fear of raising ICP, is not evidence based. Further
prospective, randomized studies need to be done before refuting the use of ketamine
in emergency settings.
Delayed Cerebral Ischemia
Another major area of focus for evaluation of uses of ketamine in neurosurgical population
is delayed cerebral ischemia (DCI). DCI is a clinical syndrome of focal neurologic
and cognitive deficits that occurs in approximately 30% of patients 3 to 14 days after
the initial subarachnoid hemorrhage (SAH).[33] While aneurysmal rebleeding is another significant complication in the initial few
hours following the bleed, DCI remains one of the most important causes of morbidity
and mortality in patients who survive to definitive aneurysm treatment.[34] Previously, it was widely established that the primary mechanism leading to delayed
neurologic deterioration after SAH was vasospasm or narrowing of caliber of cerebral
blood vessels (due to endothelial hypertrophy and vasoconstriction), leading to brain
tissue ischemia that was mediated by extravasated blood in the subarachnoid space.
However, lately, research studies have proved that looking beyond vasospasm is essential
and that a multifactorial etiology has been put forward. Among those factors, cortical
spreading depression plays a major role. The term describes a depolarization wave
in the cerebral cortex, particularly in the gray matter that propagates at 2 to 5
mm/min across the brain and results in depression of evoked and spontaneous electroencephalographic
(EEG) activity.[35] This propagation of the cortical spreading depression (CSD) wave silences spontaneous
and evoked synaptic activity in the brain for 5 to 15 minutes and is followed by spontaneous
return to normal function. It is present in the normal brain also. However, in the
injured brain, the return to normal function is prolonged, which contributes to neuronal
ischemia and microvascular dysfunction. With each wave of cortical spreading depression,
the under-perfused segments of the brain that were becoming increasingly ischemic
do not recover. It has been postulated to be one of the mechanisms in TBI and in migraine
with aura, with less severity though. Few animal studies have demonstrated the role
of ketamine in suppressing this cortical spreading depolarization.
A small randomized prospective multiple crossover trial was conducted by Carlson et
al,[36] who studied 10 patients with either SAH or TBI. A 1 × 6 electrocorticographic (ECoG)
strip was placed on the brain surface at the time of craniotomy, and patients were
then placed on a randomized alternating 6-hour dosing schedule of ketamine. It was
observed that ketamine effectively inhibits cortical spreading depolarization after
acute neurologic insult in a dose-dependent fashion (a dose of > 1.15 mg/kg/h was
required to inhibit the cortical spreading depolarization effectively). However, whether
it really contributes to a clinical benefit is not yet known. Further prospective
studies will be required to conclusively define its advantage in SAH and TBI patients.
Ischemic Stroke
Another potential area that still needs to be researched is the prevention of increase
in infarct size or volume postischemic stroke in a vast majority of patients to prevent
major morbidity and mortality. An early preclinical evidence on use of ketamine during
sedation in mice has been found to reduce infarct size post induction of ischemic
stroke and its treatment by recombinant tissue plasminogen activator for thrombolysis
by Gakuba et al.[37] Based on this study, recently KETA (Ketamine for Thrombolysis in Acute Ischemic
Stroke) trial that is a double-blinded, randomized, controlled pilot trial aiming
to determine whether co-administration of ketamine with recombinant plasminogen activator
(rtPA) for thrombolysis in acute ischemic stroke compared with rtPA co-administered
with placebo decreases cerebral infarction growth in diffusion-weighted imaging between
admission and day 1 has been initiated. Eligibility applies to 50 patients with symptomatic
ischemic stroke seen within 4.5 hours of onset with occlusion of the middle cerebral
artery (MCA) or distal internal carotid artery (ICA), and no contraindication to IV
tPA-mediated thrombolysis and eligible to endovascular treatment of stroke (i.e.,
thrombectomy). The dose of ketamine that is being investigated is 0.15 mg/kg IV (maximum
15 mg) followed by an infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg).
Analgesia and Neuroinflammation
Ketamine has also been long known for its excellent analgesia at subanesthetic doses
of 0.2 mg/kg, and this property has also been well utilized in neurosurgical group
of patients particularly post spine surgery as well as an adjuvant to local anesthetics
for infiltration to prevent post craniotomy pain.[38] A recent meta-analysis was published by Pendi et al,[39] which included 14 randomized controlled trials (RCTs) comprising 649 patients who
were administered adjunctive ketamine to reduce postoperative analgesic requirements
of opioids post spine surgery. The ketamine group had less cumulative morphine equivalent
consumption at 4, 8, 12, and 24 hours following spine surgery (p < 0.05) and lower postoperative pain scores at 6, 12, and 24 hours (p < 0.05) without any adverse events or harmful effects. Preventing central sensitization
in the dorsal horn neurons (interfere with pain transmission in spinal cord), acting
as µ receptor agonist (primarily by S-enantiomer), and inhibiting nitric oxide synthase
are some of the proposed mechanisms of pain control by ketamine. It also inhibits
IL-6, tumor necrosis factor α and IL-8 production, and other proinflammatory cytokine
activity in both central and peripheral nervous systems. It also prevents neuroinflammation
by inhibiting these cytokines in glial cells and microglia of the central nervous
system. This also has been proposed to be one of the mechanisms of neuroprotection
by ketamine. Because of its ability to inhibit neuroinflammation, it has also shown
to attenuate postoperative cognitive dysfunction particularly in the elderly after
cardiac surgery[40] and orthopaedic surgery.[41] However, this effect has not widely been extrapolated to postoperative cognitive
dysfunction occurring after most neurosurgical procedures. The reasons, however, remain
unclear and suggest that other mechanisms apart from neuroinflammation might play
a role in postoperative cognitive dysfunction post neurosurgery.
Epilepsy Surgery and Refractory Status Epilepticus
Ketamine has demonstrated both pro- and anticonvulsant properties depend on the dosage
and chronicity of the convulsive activity. In refractory and super-refractory status
epilepticus, ketamine has been used post 48 hours of seizure activity with varying
degrees of success. A dosage of 2 to 5 mg/kg to attenuate seizures has been safely
used in both adult and pediatric population.[42]
[43] During prolonged seizures, there is downregulation of GABA receptors whose activities
gradually decrease; thus, the commonly used first-and second-line antiepileptic drugs
gradually fail. Simultaneously, there is upregulation of activities of glutamatergic
NMDA receptors, often causing refractory status epilepticus and thus providing the
possibility of the use of ketamine to treat refractory status.[43] However, ketamine possesses proconvulsant properties also and is known to activate
epileptic foci, thereby having a potential role during ECoG monitoring. Ketamine significantly
caused more ECoG identifiable seizures than methohexital or thiopentone and even facilitated
extra-temporal seizure focus localization in comparison with temporal focus (p < 0.05).[44] These ECoG seizures provoked after administration of ketamine improved the localization
of the area to be resected during epilepsy surgery, more so in extratemporal epileptic
foci.[45]
Evoked Potentials
A vital part of all neurosurgical procedures is neuromonitoring, and one of the essential
intraoperative neuromonitors is evoked potential. Unfortunately, many of the general
anesthetic agents including volatile anesthetics, benzodiazepines, and high-dose barbiturates
suppress the amplitude of evoked potentials and interfere with neuromonitoring. However,
ketamine has been found in several preclinical and clinical studies to actually increase
evoked potential amplitude, and thus it may be used as an analgesic adjunct in procedures
in which evoked potential monitoring is critical. It can increase the amplitude of
the cortical somatosensory evoked potential (SSEP) and motor evoked potential (MEP)
in muscle and spinal recorded tracings after spinal stimulation.[45]
[46] This effect may be mediated by the same mechanisms that potentiate the H-reflex.
However, effects on subcortical and peripheral SSEPs are minimal, and so are effects
on myogenic MEPs.[47]
Analgosedation Regimens
Recent animal and human studies have suggested that ketamine does not alter cerebral
autoregulation,[48]
[49] and when compared with opioids such as sufentanil, it has not demonstrated any elevation
in ICP.[50] In fact, ketamine in a dose range of 1.5 to 3 mg/kg in combination with propofol
has been shown to reduce ICP in patients with TBI with no significant difference in
CPP, jugular venous oxygenation, and MCA flow, with induction of low-amplitude fast
activity EEG, with marked depression such as burst suppression.[51]
Ketamine has also demonstrated to facilitate routine bedside procedures such as endotracheal
suctioning. In a study by Caricato et al,[52] racemic ketamine (100 µg/kg/min for 10 minutes) used before endotracheal suctioning
was not associated with significant variations in CPP and jugular venous oxygenation
although ketamine was not effective in controlling ICP elevation during this time
completely. Ketamine has often been used in conjunction with midazolam or propofol,[14] and the concurrent use results in less requirements of vasopressors.[9] It is also well suited for analgosedation after major spine surgeries with an added
opioid sparing effect.
Oral ketamine has been successfully used to treat central neuropathic pain as well
as post stroke and thalamic pain, which were refractory to conventional pain treatments
in recently published case reports.[53]
[54] However, the side effects of ketamine such as dysphoria, hallucinations, and paranoid
feelings were attenuated by the concurrent use of benzodiazepines.
